LifeArc Ventures
Corporate VCLondon · Seed–Growth · 12 people tracked
Investment thesis
LifeArc Ventures invests from Seed to Series B in therapeutics and medtech companies across all therapeutic areas and a diverse range of modalities, co-investing alongside other leading life sciences venture funds globally. As part of LifeArc, a self-funded medical research organisation, it offers portfolio companies a combination of scientific, commercial and financial support, drawing on access to leading scientists with deep translational science expertise. The team blends financial, operational and scientific experience spanning venture capital, investment banking, pharma and biotech business development, and clinical practice. It seeks companies with the potential to deliver meaningful patient impact while generating returns that LifeArc can reinvest in its core objectives.
Source: firm website, verified Aug 7, 2026.
Team · 12 people
from the firm's website
What they invest in
from 19 of 23 portfolio companiesBiotech ×17Healthtech ×14Digital Health ×6Medical Devices ×5Deep Tech ×4AI & Machine Learning ×2Longevity ×2Consumer ×1
HQs:United Kingdom×5Germany×2United States×2Belgium×1Canada×1
Who they back
founder profiles across 11 portfolio companiesFounding team size:solo founder×52 founders×43 founders×2
Investments · 23 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 12023 · 13 dated
Ikarovec is a biotech company focused on developing treatments for retinal diseases affecting vision.
BiotechDeep TechDigital HealthHealthtechMedical DevicesNorwich, GB
Peter Widdowson, PhD(Scientific Founder)Thomas Ciulla, M.D, MBA(President and Chief Executive Officer)
Co-investorsFuture Planet CapitalUK Innovation & Science Seed Fund
Maxion Therapeutics develops protein and antibody therapeutics using its patented KnotBody technology, which fuses cysteine-rich miniproteins (Knottins) into antibody binding loops to target ion channels and GPCRs.
BiotechHealthtechCambridge, GB
John McCafferty(Co-founder and CTO)inAneesh Karatt-Vellatt(Co-founder and CSO)in
Co-investorsMonograph Capital PartnersGeneral CatalystSolasta Ventures
Affect Therapeutics operates an app-based digital treatment provider offering care for substance use disorders (alcohol, cannabis, opioid) and mental health conditions like depression and anxiety, using methods such as contingency management, CBT, medication-assisted treatment, and peer support.
Digital HealthHealthtechMental HealthNew York, US
Jeff DeFlavio(Co-founder)inKristin Muhlner(Executive Officer, Director)in
BoardKevin Ryan(Director)Jeff Rinehart(Director)in
Co-investorsArtis VenturesCity LightAlleyCorpSamsung NextWhat If VenturesAllumia Ventures
Gene therapy company developing transformative medicines for neurodegenerative disorders.
Co-investorsF-Prime Capital
AviadoBio is a gene therapy company developing adeno-associated viral (AAV) treatments for neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
BiotechDeep TechDigital HealthHealthtech
Chris Shaw(Co-Founder & Chief Scientific and Clinical Advisor)inDo Young Lee(Co-Founder)Youn Bok Lee(Co-Founder)inLisa Deschamps(Chief Executive Officer)inGraeme Fielder(Chief Operating Officer)inAlex Bloom(Chief Development Officer)in
Co-investorsAdvent Life SciencesDementia DiscoveryF-Prime CapitalMonograph Capital PartnersNew Enterprise Associates (NEA)
Climb Bio develops monoclonal antibody therapies for immune-mediated diseases, advancing clinical-stage candidates such as budoprutug for conditions including immune thrombocytopenia.
BiotechHealthtech
Aoife Brennan, MB, ChB(President and Chief Executive Officer)Perrin Wilson, PhD(Chief Business Officer)Susan Altschuller, PhD, MBA(Chief Financial Officer)Edgar Charles, MD(Chief Medical Officer)Ashley Jones(Senior Vice President, People & Workforce Strategy)Adam Villa, MBA, MS(Senior Vice President, Technical Operations)
Corteria Pharma develops interceptive therapies aimed at treating subpopulations of patients with heart failure, sarcopenia, and obesity.
BiotechDigital HealthHealthtechLongevity
Philip JaniakinMarie-Laure OzouxinRégis OlivierinFrancesca C. LawsonMark KowalaEleonore Jouannyin
Co-investorsFountain Healthcare PartnersJeito CapitalKurma PartnersOrbiMedV-Bio VenturesOmnes Capital+1 more
NeuLogiq is a research platform for clinical trials that integrates tablet-based cognitive assessments, EEG monitoring, and real-world behavioral data to measure brain function changes.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBelfast, GB
Brian Murphy(Co-Founder & CSO)inTina(CEO)
Co-investorsDementia Discovery FundClarendon Fund Managers Ltd.
Cytospire Therapeutics develops multispecific antibodies and next-generation γδ T cell engagers designed to direct innate and adaptive immune effector cells as an alternative to CD3-based engagers.
BiotechHealthtech
Co-investorsCriteria Bio VenturesMedical Incubator Japan K.K.Modi VenturesPathway BioventuresSound Bioventures
Droia Ventures is a specialist venture capital firm investing globally in early-stage drug development companies focused on therapeutics for oncology and genetic disease.
BiotechLeuven, BE
Co-investorsClavystBioFrazier Life SciencesNovo Holdings
Exciva is a company focused on neurological and neurodegenerative conditions, led by a team with expertise in chemistry, clinical operations, and regulatory affairs.
BiotechDigital HealthLongevityMedical DevicesHeidelberg, DE
Hans Moebius(Co-founder and CMO, Head of Clinical Operations)Anton Bespalov(Co-founder and CSO, Head of Regulatory Affairs)
Co-investorsAndera PartnersFountain Healthcare PartnersModi Ventures
Fluid Biomed develops a bioresorbable polymer-based stent designed to treat brain aneurysms by diverting blood flow and reducing risk of stroke.
BiotechDeep TechHealthtechMedical DevicesCalgary, CA
Dr. John H. Wong(Co-founder & Chief Executive Officer)Dr. Alim P. Mitha(Co-founder, President & Chief Technology Officer)
Co-investorsAccelerate FundShangBay Capital LLCThin Air LabsUCeed Funds
GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.
BiotechHealthtechNewton, US
Ganesh V. Kaundinya(President & CEO)in
Co-investors5AM VenturesCatalio Capital Management, LPRoche Venture FundSixty Degree CapitalSofinnova PartnersAgent Capital+1 more
Hillstar Bio develops precision immunotherapies for autoimmune diseases, using antibody engineering to selectively deplete pathogenic immune cells while sparing healthy ones.
BiotechHealthtech
Co-investorsDroia VenturesFrazier Life Sciences
A UK-based preclinical biotechnology company developing antibody drugs against ion channels and GPCRs using proprietary KnotBody technology.
Co-investorsGeneral CatalystMonograph Capital Partners
MC Sciences is a biotech company developing first-in-class mast cell therapeutics based on a discovered mast cell receptor, aimed at diseases across immunology, dermatology, respiratory, gastrointestinal, fibrotic and chronic inflammatory conditions such as chronic urticaria, systemic mastocytosis, COPD, asthma and MCAS.
BiotechHealthtech
Gerhard J. Molderings(Founder)Wolfgang Taumann(CEO & Co-Founder)in
BoardMikael Dolsten(Board Chairman)
Co-investorsROC Venture Group
Ozlo manufactures sleep wellness products including blackout sleep masks and audio devices designed to improve sleep quality through light and sound control.
ConsumerHardwareWellness & Fitness
Co-investorsArtis Ventures
Developing PTD802, a therapeutic candidate for multiple sclerosis (received FDA IND clearance).
Co-investorsAdvent Life Sciences
Pheno Therapeutics is a clinical-stage biotech company developing GPR17 antagonists that target oligodendrocytes to promote brain repair.
BiotechMedical DevicesEdinburgh, GB
Neil Carragher(Founder)in
Co-investorsAdvent Life Sciences
RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease.
BiotechHealthtech
Co-investorsFrazier Life Sciences
T-Cypher Bio develops drugs with curative potential, focusing on antibody development, T cell biology, and TCR discovery.
AI & Machine LearningBiotechDeep Tech
Co-investorsFuture Planet CapitalOxford Science EnterprisesPerivoli Innovations
Tribune Therapeutics is a preclinical biopharmaceutical company developing medicines that target CCN protein family signaling (such as CCN2/CTGF) to block fibrotic pathways.
BiotechHealthtech
Ole Kaasbøll(Co-founder)
Co-investorsHealthCapIndustrifondenInvestinorNovo Holdings
Portfolio news
latest coverage across their companiesAffect Therapeutics · bhbusiness.com · Nov 5, 2025
GlycoEra · cen.acs.org · Jul 25, 2025
Tribune Therapeutics AB · biospace.com · Mar 27, 2025
Frequently asked questions
- How many investments has LifeArc Ventures made?
- LifeArc Ventures has 22 tracked investments, including 1 dated in the last 24 months.
- What stage does LifeArc Ventures invest at?
- LifeArc Ventures invests at the Seed, Series A, Series B, Series C, Growth stages.
- What sectors does LifeArc Ventures focus on?
- LifeArc Ventures focuses on Biotech, Digital Health, Healthtech, IoT, Medical Devices.
- Where is LifeArc Ventures located?
- LifeArc Ventures is headquartered in London, GB.
- Does LifeArc Ventures lead rounds?
- Yes, LifeArc Ventures leads investment rounds.
- Who does LifeArc Ventures co-invest with?
- LifeArc Ventures most often shares deals with Advent Life Sciences, Monograph Capital Partners, Artis Ventures, among 40 tracked co-investors.
Similar investors
Ambix is a healthcare-focused investment firm that provides funding, strategy, and hands-on support to companies developing medical tools and devices, biochemistry-based technologies, digital health applications, and other novel healthcare solutions. It invests across all stages and also builds companies itself.
MDI Ventures is the corporate venture capital arm of Telkom Indonesia, investing in and building synergies between technology startups and Indonesian enterprises. It manages a multi-fund platform (including Centauri Fund, Arise, and sector-specific funds) with a portfolio of 80+ companies.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
SBCVC (SoftBank China Venture Capital) is a venture capital and private equity fund management firm founded in 2000, focused on investing in high-growth, high-tech companies in Greater China.
Olive Tree Capital invests in technology and life sciences companies, backing entrepreneurs across healthcare, fintech, enterprise, AI/ML, and frontier technology sectors.